| Acquired by | Pfizer |
| Price | $56M |
| Date | 10/11 |
| Website | icagen.com |
| Category | BioTech |
| Phone | 919-941-5206 |
| Employees | |
| Founded | 1992 |
| Description | biotechnology company |
| Unattributed, 9/09 Pfizer Strategic Investments | $5M |
Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. It develops ICA-105665 that is in Phase I single dose escalation study in healthy volunteers for epilepsy and neuropathic pain; and Senicapoc, which is in Phase I multiple dose study in healthy volunteers for the treatment of asthma. The company also conducts ongoing drug discovery programs on new therapeutics for pain and inflammatory disorders. Icagen has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma, Inc.; and Pfizer, Inc. The company was founded in 1992 and is based in Durham, North Carolina.
